Cubist Pharmaceuticals Issues Voluntary U.S. Recall Of Certain Lots Of CUBICIN (Daptomycin For Injection) 500 mg In 10 mL Single Use Vials Due To Presence Of Particulate Matter

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Cubist Pharmaceuticals Issues Voluntary U.S. Recall Of Certain Lots Of CUBICIN (Daptomycin For Injection) 500 mg In 10 mL Single Use Vials Due To Presence Of Particulate Matter

08/07/2014 02:29 PM EDT

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling certain lots of CUBICIN® (daptomycin for injection) to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer. Please click here for the list of affected CUBICIN lot information.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? Please visit subscriberhelp.govdelivery.com
• Other inquiries? webmail@oc.fda.gov

---

This email was sent to filter@clubhouseb.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420